| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Annals of Thoracic Surgery, Vol 55, 971-976, Copyright © 1993 by The Society of Thoracic Surgeons
BP Bidstrup, J Harrison, D Royston, KM Taylor and T Treasure
Aprotinin, a serine protease inhibitor, has recently been shown to reduce
blood loss in cardiac surgical patients. Data on the safety and efficacy of
aprotinin therapy administered to 671 cardiac surgical patients in 41
United Kingdom cardiac surgical units have been submitted to interim
analysis. The patients studied were in high-risk categories for excessive
bleeding, including 457 redo operations and 79 patients with active
infective endocarditis. Overall mortality was 12% in redo cases and 5.1% in
first-time operations. Adverse events were reported in only 20 patients
(3%). Median blood loss at 24 hours after operation was 400 mL, and median
transfusion volume throughout the operative and postoperative period was 2
units. These data confirm that the use of aprotinin therapy in high-risk
cardiac surgical patients is associated with a low incidence of adverse
events.
ARTICLES
Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom
Cardiothoracic Unit, Wellington Hospital, London, United Kingdom.
This article has been cited by other articles:
|
|
 |
|
  D. Pagano, N. J. Howell, N. Freemantle, D. Cunningham, R. S. Bonser, T. R. Graham, J. Mascaro, S. J. Rooney, I. C. Wilson, R. Cramb, et al. Bleeding in cardiac surgery: The use of aprotinin does not affect survival J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Body and C. D. Mazer Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Arnold, D. A. Fergusson, A. K.C. Chan, R. J. Cook, G. A. Fraser, W. Lim, M. A. Blajchman, and D. J. Cook Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth. Analg., March 1, 2006; 102(3): 731 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G Raja and G. D Dreyfus Modulation of Systemic Inflammatory Response after Cardiac Surgery Asian Cardiovasc Thorac Ann, December 1, 2005; 13(4): 382 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Beierlein, A. M. Scheule, W. Dietrich, and G. Ziemer Forty Years of Clinical Aprotinin Use: A Review of 124 Hypersensitivity Reactions Ann. Thorac. Surg., February 1, 2005; 79(2): 741 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Karski and J. T. Balatbat Blood Conservation Strategies in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188. [Abstract] [PDF]
|
|
|
|
|
|
Y. Deng, K. Byth, and H. S Paterson Age and Left Ventricular Impairment Predict Reopening for Bleeding Asian Cardiovasc Thorac Ann, June 1, 2003; 11(2): 147 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Landis Aprotinin: Antithrombotic and Vasoactive Mechanisms of Action Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 307 - 312. [Abstract] [PDF]
|
|
|
|
|
|
R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Landis, D. O. Haskard, and K. M. Taylor New antiinflammatory and platelet-preserving effects of aprotinin Ann. Thorac. Surg., November 1, 2001; 72(5): S1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-O. Defraigne, J. Pincemail, G. Dekoster, R. Larbuisson, M. Dujardin, F. Blaffart, J.-L. David, and R. Limet SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery Ann. Thorac. Surg., December 1, 2000; 70(6): 2075 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Wong, R. F. McLean, S. E. Fremes, K. A. Deemar, E. M. Harrington, G. T. Christakis, and B. S. Goldman Aprotinin and tranexamic acid for high transfusion risk cardiac surgery Ann. Thorac. Surg., March 1, 2000; 69(3): 808 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ray, K. F. Brown, C. A. Burrows, and M. F. O’Brien Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass Ann. Thorac. Surg., September 1, 1999; 68(3): 940 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Savarese, H. Waitkus, F. M. Stewart, and M. Callery Bloodless Medicine and Surgery J Intensive Care Med, January 1, 1999; 14(1): 20 - 33. [PDF]
|
|
|
|
|
|
T. P. Carrel, M. Schwanda, P. R. Vogt, and M. I. Turina Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only Ann. Thorac. Surg., July 1, 1998; 66(1): 153 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Maquelin, R. J. Berckmans, R. Nieuwland, M. C. L. Schaap, K. ten Have, L. Eijsman, and A. Sturk Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1160 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Sowade, H. Warnke, P. Scigalla, B. Sowade, W. Franke, D. Messinger, and J. Gross Avoidance of Allogeneic Blood Transfusions by Treatment With Epoetin Beta (Recombinant Human Erythropoietin) in Patients Undergoing Open-Heart Surgery Blood, January 15, 1997; 89(2): 411 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ray, BAppSc, N. A. Marsh, S. J. E. Just, BAppSc, E. J. Perrin, BAppSc, M. F. O'Brien, and G. A. T. Hawson Preoperative Platelet Dysfunction Increases the Benefit of Aprotinin in Cardiopulmonary Bypass Ann. Thorac. Surg., January 1, 1997; 63(1): 57 - 63. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ashraf, Y. Tian, D. Cowan, U. Nair, R. Chatrath, N. R. Saunders, K. G. Watterson, and P. G. Martin ""Low-Dose"" Aprotinin Modifies Hemostasis but Not Proinflammatory Cytokine Release Ann. Thorac. Surg., January 1, 1997; 63(1): 68 - 73. [Abstract] [Full Text]
|
|
|
|
|
|
A. M. Scheule, M. J. Jurmann, H. P. Wendel, L. Haberle, F. S. Eckstein, and G. Ziemer Anaphylactic Shock After Aprotinin Reexposure: Time Course of Aprotinin-Specific Antibodies Ann. Thorac. Surg., January 1, 1997; 63(1): 242 - 244. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Lemmer Jr, E. W. Dilling, J. R. Morton, J. B. Rich, F. Robicsek, D. L. Bricker, C. B. Hantler, J. G. Copeland III, J. L. Ochsner, P. O. Daily, et al. Aprotinin for Primary Coronary Artery Bypass Grafting: A Multicenter Trial of Three Dose Regimens Ann. Thorac. Surg., December 1, 1996; 62(6): 1659 - 1668. [Abstract] [Full Text]
|
|
|
|
|
|
M.-C. Seghaye, J. Duchateau, R. G. Grabitz, K. Jablonka, T. Wenzl, C. Marcus, B. J. Messmer, and G. von Bernuth Influence of Low-Dose Aprotinin on the Inflammatory Reaction Due to Cardiopulmonary Bypass in Children Ann. Thorac. Surg., April 1, 1996; 61(4): 1205 - 1211. [Abstract] [Full Text]
|
|
|
|
|
|
S. K. Ohri, R. Paratt, J. M. Becket, J. Brannan, B. J. Hunt, and K. M. Taylor Genetically Engineered Serine Protease Inhibitor for Hemostasis After Cardiac Operations Ann. Thorac. Surg., April 1, 1996; 61(4): 1223 - 1230. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Hornick and A. George Blood contact activation: pathophysiological effects and therapeutic approaches Perfusion, January 1, 1996; 11(1): 3 - 19. [PDF]
|
|
|
|
|
|
J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al. A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting Circulation, October 15, 1995; 92(8): 2236 - 2244. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Goldstein, J. A. Seldomridge, J. M. Chen, K. A. Catanese, C. M. DeRosa, A. D. Weinberg, C. R. Smith, E. A. Rose, H. R. Levin, and M. C. Oz Use of Aprotinin in LVAD Recipients Reduces Blood Loss, Blood Use, and Perioperative Mortality Ann. Thorac. Surg., May 1, 1995; 59(5): 1063 - 1067. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Lemmer Jr, W. Stanford, S. L. Bonney, E. V. Chomka, R. B. Karp, G. W. Laub, J. A. Rumberger, and H. V. Schaff Aprotinin for Coronary Artery Bypass Grafting: Effect on Postoperative Renal Function Ann. Thorac. Surg., January 1, 1995; 59(1): 132 - 136. [Abstract] [Full Text]
|
|
|
|
|
|
B. Blauhut, W. Harringer, P. Bettelheim, J. E. Doran, P. Spath, and P. Lundsgaard-Hansen Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1083 - 1091. [Abstract] [Full Text]
|
|
|
|
|
|
P. O. Daily, J. A. Lamphere, W. P. Dembitsky, R. M. Adamson, and N. F. Dans Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass graftingA randomized, prospective, double-blind study J. Thorac. Cardiovasc. Surg., July 1, 1994; 108(1): 99 - 108. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Murkin, J. Lux, N. A. Shannon, G. M. Guiraudon, A. H. Menkis, F. N. McKenzie, and R. J. Novick Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 554 - 561. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
